NeuroMetrix Inc
NASDAQ:NURO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NeuroMetrix Inc
Cash from Financing Activities
NeuroMetrix Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NeuroMetrix Inc
NASDAQ:NURO
|
Cash from Financing Activities
$1.5m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
136%
|
CAGR 10-Years
-15%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Financing Activities
-$395m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Financing Activities
-$956.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Financing Activities
$113m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Financing Activities
-$6.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Financing Activities
-$2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-94%
|
CAGR 10-Years
N/A
|
|
NeuroMetrix Inc
Glance View
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. The company is headquartered in Waltham, Massachusetts and currently employs 23 full-time employees. The company went IPO on 2004-07-22. The firm is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. The company has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.
See Also
What is NeuroMetrix Inc's Cash from Financing Activities?
Cash from Financing Activities
1.5m
USD
Based on the financial report for Dec 31, 2024, NeuroMetrix Inc's Cash from Financing Activities amounts to 1.5m USD.
What is NeuroMetrix Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-15%
Over the last year, the Cash from Financing Activities growth was -37%. The average annual Cash from Financing Activities growth rates for NeuroMetrix Inc have been -58% over the past three years , 136% over the past five years , and -15% over the past ten years .
